Balyasny Asset Management
ORIC icon

Balyasny Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Balyasny Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.64M Sell
523,790
-426,424
-45% -$4.84M 0.01% 1238
2025
Q4 		$7.77M Sell
950,214
-569,100
-37% -$6.55M 0.01% 1160
2025
Q3 		$18.2M Sell
1,519,314
-258,430
-15% -$2.72M 0.02% 759
2025
Q2 		$18M Sell
1,777,744
-229,528
-11% -$1.54M 0.03% 707
2025
Q1 		$11.2M Buy
2,007,272
+452,012
+29% +$3.95M 0.02% 855
2024
Q4 		$12.6M Buy
1,555,260
+424,194
+38% +$3.89M 0.02% 868
2024
Q3 		$11.6M Buy
+1,131,066
New +$11.2M 0.02% 869
2023
Q2 		– Sell
-11,725
Closed -$66.8K – 2648
2023
Q1 		$66.8K Buy
+11,725
New +$61.3K ﹤0.01% 2355
2022
Q4 		– Sell
-13,557
Closed -$43K – 3109
2022
Q3 		$43K Buy
+13,557
New +$54.3K ﹤0.01% 2492

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Balyasny Asset Management's ORIC Position: Q1 2026 in Review

Balyasny Asset Management reduced its Oric Pharmaceuticals (ORIC) stake by 45% in Q1 2026, selling an estimated $4.84M and leaving 523,790 shares worth $6.64M. The position accounts for 0.01% of the portfolio, ranked #1238.

Balyasny Asset Management first reported a position in ORIC in Q3 2022 and has held it in 9 quarters since. The position peaked at $18.2M in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Balyasny Asset Management held 523,790 shares of Oric Pharmaceuticals worth $6.64M as of Q1 2026.
  • Balyasny Asset Management sold 426,424 Oric Pharmaceuticals shares in Q1 2026, an estimated $4.84M.
  • Oric Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1238 holding.
  • Balyasny Asset Management first reported a position in Oric Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
  • Balyasny Asset Management's Oric Pharmaceuticals position peaked at $18.2M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.